CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.…
CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference
CNS Pharmaceuticals (NASDAQ: CNSP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 8 employees.
The shares were at 3.560 USD on 20 November 2026, down 47.8% over 52 weeks. Its 52-week range is 1.900 USD to 10.54 USD: the price is 66.2% below the high and 87.4% above the low.
Its market capitalisation is 5.25M USD.
CNS Pharmaceuticals reports return on equity of -350.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 19.98M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.